Royalty Pharma (RPRX)
(Real Time Quote from BATS)
$26.74 USD
+0.30 (1.14%)
Updated Aug 13, 2024 10:40 AM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Royalty Pharma (RPRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$44.29 | $60.00 | $28.00 | 67.51% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Royalty Pharma comes to $44.29. The forecasts range from a low of $28.00 to a high of $60.00. The average price target represents an increase of 67.51% from the last closing price of $26.44.
Analyst Price Targets (7 )
Broker Rating
Royalty Pharma currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 57.14% and 28.57% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 28.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RPRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 5 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.21 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | UBS | Ashwani Verma | Strong Buy | Hold |
4/1/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
2/20/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
2/2/2024 | Tigress Financial Partners | Ivan Feinseth | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 7 |
Average Target Price | $44.29 |
LT Growth Rate | 1.70% |
Industry | Financial - Miscellaneous Services |
Industry Rank by ABR | 85 of 253 |
Current Quarter EPS Est: | 0.92 |